Shares of Stemline Therapeutics Inc (NASDAQ:STML) have been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $33.75.
A number of equities analysts have issued reports on STML shares. Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research report on Friday, February 2nd. ValuEngine upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 26th.
In related news, insider David Gionco sold 4,250 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total transaction of $57,077.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The disclosure for this sale can be found here. Insiders sold 47,887 shares of company stock worth $681,287 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.
Stemline Therapeutics (NASDAQ:STML) traded down $0.05 during trading on Wednesday, reaching $15.90. 201,500 shares of the company’s stock traded hands, compared to its average volume of 328,594. The company has a market capitalization of $460.65, a P/E ratio of -6.19 and a beta of -0.02. Stemline Therapeutics has a 1-year low of $6.35 and a 1-year high of $17.40.
ILLEGAL ACTIVITY WARNING: “Brokerages Set Stemline Therapeutics Inc (STML) PT at $33.75” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/19/brokerages-set-stemline-therapeutics-inc-stml-pt-at-33-75.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.